Daybu (trofinetide)

Where it stands

Daybu (trofinetide) is authorised in the EU. The European Commission decision was dated 2026-08-20, and the marketing authorisation is held by Acadia Pharmaceuticals B.V. The product is listed under the therapeutic area Rett syndrome.

The authorised indication is the treatment of neurobehavioural symptoms of Rett syndrome in adults and paediatric patients aged 5 years and older. The records give the indication wording only. They contain no efficacy data, pivotal trial details or product-information text, so this analysis does not characterise the clinical evidence.

The same substance is recorded elsewhere as Daybue Stix, which is approved in the US. The records give no US approval date, indication wording or label details. They also do not say whether the EU and US terms match, so no comparison is made.

Regulatory pathway and designations

Two milestones are recorded. The CHMP gave a positive opinion on 2026-06-25, and the EC approved the product on 2026-08-20, 56 days later. In the centralised procedure, the CHMP opinion is a scientific recommendation. The legally binding authorisation follows as a European Commission decision, which is normally issued within about two months of the opinion. That is consistent with this timeline.

Daybu carries two designations: Orphan and Additional monitoring. Orphan status relates to a rare condition and is intended to encourage development in areas of high unmet need. The records do not state the procedure type (for example standard, conditional or exceptional circumstances). They also do not say whether orphan status was reviewed at the time of authorisation or give any market-exclusivity details, so none of these should be inferred.

The records do not describe the review timetable, any clock-stops, or the assessment history before the CHMP opinion.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse-reaction profile, contraindications, warnings or risk management plan content, so none is described here.

The one pharmacovigilance-relevant fact is the Additional monitoring designation. In the EU, such products are subject to intensified safety surveillance. Their product information carries a black inverted triangle and a statement encouraging healthcare professionals and patients to report suspected adverse reactions. The designation is not in itself a finding of a safety concern.

Any specific monitoring obligations, such as post-authorisation studies or conditions attached to the authorisation, are not covered by the records.

What to watch

The first priority is the published EU product information and the European Public Assessment Report. These will show the evidence base, the benefit-risk reasoning, any conditions or obligations, and the risk-minimisation measures. The records do not include them.

The second is commercial availability. Country-by-country launch, pricing, reimbursement and health technology assessment outcomes are not covered by the records and will determine real-world access in the EU.

The third is how the EU position develops alongside the US product, Daybue Stix. Differences in indication, age range or labelling between the two regions can only be assessed once the full texts are compared. Early post-marketing safety reporting is also worth tracking, given the Additional monitoring status.